Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GEH300079 (68Ga)
- Development stage
- Phase 3
- Lead developer
- GE Healthcare
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
GEH300079 (68Ga) is a radiopharmaceutical imaging agent developed by GE Healthcare for the detection of peritoneal carcinomatosis (PC) using Positron Emission Tomography (PET)/Computed Tomography (CT). It consists of a targeting ligand labeled with the positron-emitting radioisotope Gallium-68 (68Ga). The agent is designed to improve the visualization of peritoneal metastases in patients with colorectal, gastric, ovarian, or pancreatic cancers, where standard-of-care imaging often lacks sensitivity. GEH300079 targets fibroblast activation protein (FAP), which is highly expressed in the cancer-associated fibroblasts of the tumor stroma. It is currently being evaluated in the Phase 2/3 PERISCOPE clinical trial to assess its diagnostic performance and compare it against institutional standard-of-care imaging methods.
- Other names
- GEH300079 (68Ga) Injection68Ga-GEH300079[68Ga]GEH300079
02
Targets
FAP (Fibroblast activation protein alpha)
Beyond the preview
Go deeper on GEH300079 (68Ga).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GEH300079 (68Ga).